Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Michigan

Sites in Ann Arbor, MI

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1232
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Michigan, Ann Arbor, MI
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Michigan, Ann Arbor, MI. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 469–480 of 1,232 matching trials with a site at University of Michigan, Ann Arbor, MI.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Results available

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01585805
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976
Site status not listed — check the official record
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Epcoritamab, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years to 79 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
68
States / cities
Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)

NCT05508971
Status at this site: Recruiting
View directory record Official record
Conditions
Obstructive Sleep Apnea, Down Syndrome
Interventions
DISE-Directed Surgery, Adenotonsillectomy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 17 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Aurora, Colorado • Ann Arbor, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

NCT05753748
Status at this site: Recruiting
View directory record Official record
Conditions
Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Endoscopic Eradication Therapy
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

NCT06783309
Status at this site: Recruiting
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions
CNP-103, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
45
States / cities
Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754
Site status not listed — check the official record
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Oakland, California • Roseville, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Cephea Early Feasibility Study

NCT05061004
Status at this site: Recruiting
View directory record Official record
Conditions
Mitral Regurgitation
Interventions
Cephea Mitral Valve System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Active, not recruiting No phase listed Observational

Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

NCT03878550
Site status not listed — check the official record
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Cirrhosis, Liver
Interventions
Not listed
Lead sponsor
Glycotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445
Status at this site: Recruiting
View directory record Official record
Conditions
Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Interventions
ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham
Drug · Other
Lead sponsor
ONL Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Active, not recruiting Not applicable Interventional Results available

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1

NCT02777528
Site status not listed — check the official record
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic, Aorta, Lesion
Interventions
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
Device · Procedure
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
34
States / cities
Los Angeles, California • Stanford, California • Hartford, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Recruiting Not applicable Interventional

Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)

NCT07582861
Status at this site: Recruiting
View directory record Official record
Conditions
Congenital Heart Disease (CHD)
Interventions
HeartGPS
Other
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 2:12 PM EDT
Active, not recruiting Phase 3 Interventional

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

NCT05438212
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain
Interventions
Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
208
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 154 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 27, 2026, 2:12 PM EDT

About this University of Michigan institution page

What this page lists
ClinicalTrials.gov records that list University of Michigan in Ann Arbor, MI as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.